ColombiaTuberculosis profile
Population  2014 48 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.73 (0.71–0.75) 1.5 (1.5–1.6)
Mortality (HIV+TB only) 0.4 (0.3–0.51) 0.84 (0.64–1.1)
Prevalence  (includes HIV+TB) 19 (9.4–31) 39 (20–64)
Incidence  (includes HIV+TB) 16 (14–17) 33 (29–37)
Incidence (HIV+TB only) 3.4 (2.9–3.9) 7.1 (6.1–8.2)
         
Case detection, all forms (%) 76 (68–86)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.4 (1.6–3.6) 13 (9.6–17)
MDR-TB cases among notified pulmonary
TB cases
220 (140–320) 140 (110–180)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 7 073   415
Pulmonary, clinically diagnosed 1 949   117
Extrapulmonary 2 289   32
       
Total new and relapse 11 875    
Previously treated, excluding relapses 560    
Total cases notified 12 435    
Among 11 875 new and relapse cases:
590 (5%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 3 484 (49%) 535 (48%) 4 134
Laboratory-confirmed RR-/MDR-TB cases     187
Patients started on MDR-TB treatment ***     173
TB/HIV 2014 Number (%)
TB patients with known HIV status 9 994 (80)
HIV-positive TB patients 2 143 (21)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 901 (42)
HIV-positive TB patients on antiretroviral therapy (ART) 816 (38)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (71) 11 902
Previously treated cases, excluding relapse, registered in 2013 (42) 708
HIV-positive TB cases, all types, registered in 2013 (45) 1 489
RR-/MDR-TB cases started on second-line treatment in 2012 (48) 99
XDR-TB cases started on second-line treatment in 2012 (25) 4
Laboratories 2014  
Smear (per 100 000 population) 4.3
Culture (per 5 million population) 110.1
Drug susceptibility testing (per 5 million population) 0.5
Sites performing Xpert MTB/RIF 18
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 12
% Funded domestically 61%
% Funded internationally 15%
% Unfunded 24%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-25 Data: www.who.int/tb/data